Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi.
Child
Child, Preschool
Double-Blind Method
Female
Humans
Immunogenicity, Vaccine
Incidence
Infant
Malawi
Male
Salmonella typhi
Treatment Outcome
Typhoid Fever
/ prevention & control
Typhoid-Paratyphoid Vaccines
/ administration & dosage
Vaccination
Vaccines, Conjugate
/ administration & dosage
World Health Organization
Africa
Malawi
TyVAC
children/pediatric
typhoid conjugate vaccine
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
07 03 2019
07 03 2019
Historique:
entrez:
8
3
2019
pubmed:
8
3
2019
medline:
29
5
2020
Statut:
ppublish
Résumé
Typhoid fever is an acute infection characterized by prolonged fever following the ingestion and subsequent invasion of Salmonella enterica serovar Typhi (S. Typhi), a human-restricted pathogen. The incidence of typhoid fever has been most reported in children 5-15 years of age, but is increasingly recognized in children younger than 5 years old. There has been a recent expansion of multidrug-resistant typhoid fever globally. Prior typhoid vaccines were not suitable for use in the youngest children in countries with a high burden of disease. This study aims to determine the efficacy of a typhoid conjugate vaccine (TCV) that was recently prequalified by the World Health Organization, by testing it in children 9 months through 12 years of age in Blantyre, Malawi. In this Phase III, individually randomized, controlled, double-blind trial of the clinical efficacy of TCV, 28 000 children 9 months through 12 years of age will be enrolled and randomized in a 1:1 ratio to receive either Vi-TCV or a meningococcal serogroup A conjugate vaccine. A subset of 600 of these children will be further enrolled in an immunogenicity and reactogenicity sub-study to evaluate the safety profile and immune response elicited by Vi-TCV. Recruiting began in February 2018. All children will be under passive surveillance for at least 2 years to determine the primary outcome, which is blood culture-confirmed S. Typhi illness. Children enrolled in the immunogenicity and reactogenicity sub-study will have blood drawn before vaccination and at 2 timepoints after vaccination to measure their immune response to vaccination. They will also be followed actively for adverse events and serious adverse events. The introduction of a single-dose, efficacious typhoid vaccine into countries with high burden of disease or significant antimicrobial resistance could have a dramatic impact, protecting children from infection and reducing antimicrobial usage and associated health inequity in the world's poorest places. This trial, the first of a TCV in Africa, seeks to demonstrate the impact and programmatic use of TCVs within an endemic setting. NCT03299426.
Sections du résumé
BACKGROUND
Typhoid fever is an acute infection characterized by prolonged fever following the ingestion and subsequent invasion of Salmonella enterica serovar Typhi (S. Typhi), a human-restricted pathogen. The incidence of typhoid fever has been most reported in children 5-15 years of age, but is increasingly recognized in children younger than 5 years old. There has been a recent expansion of multidrug-resistant typhoid fever globally. Prior typhoid vaccines were not suitable for use in the youngest children in countries with a high burden of disease. This study aims to determine the efficacy of a typhoid conjugate vaccine (TCV) that was recently prequalified by the World Health Organization, by testing it in children 9 months through 12 years of age in Blantyre, Malawi.
METHODS
In this Phase III, individually randomized, controlled, double-blind trial of the clinical efficacy of TCV, 28 000 children 9 months through 12 years of age will be enrolled and randomized in a 1:1 ratio to receive either Vi-TCV or a meningococcal serogroup A conjugate vaccine. A subset of 600 of these children will be further enrolled in an immunogenicity and reactogenicity sub-study to evaluate the safety profile and immune response elicited by Vi-TCV. Recruiting began in February 2018.
RESULTS
All children will be under passive surveillance for at least 2 years to determine the primary outcome, which is blood culture-confirmed S. Typhi illness. Children enrolled in the immunogenicity and reactogenicity sub-study will have blood drawn before vaccination and at 2 timepoints after vaccination to measure their immune response to vaccination. They will also be followed actively for adverse events and serious adverse events.
CONCLUSIONS
The introduction of a single-dose, efficacious typhoid vaccine into countries with high burden of disease or significant antimicrobial resistance could have a dramatic impact, protecting children from infection and reducing antimicrobial usage and associated health inequity in the world's poorest places. This trial, the first of a TCV in Africa, seeks to demonstrate the impact and programmatic use of TCVs within an endemic setting.
CLINICAL TRIALS REGISTRATION
NCT03299426.
Identifiants
pubmed: 30845320
pii: 5371220
doi: 10.1093/cid/ciy1103
pmc: PMC6405268
doi:
Substances chimiques
Typhoid-Paratyphoid Vaccines
0
Vaccines, Conjugate
0
Banques de données
ClinicalTrials.gov
['NCT03299426']
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
S50-S58Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
PLoS Negl Trop Dis. 2017 Feb 27;11(2):e0005376
pubmed: 28241011
mBio. 2018 Feb 20;9(1):
pubmed: 29463654
Vaccine. 2017 Jun 14;35(27):3506-3514
pubmed: 28527687
Bull World Health Organ. 2004 May;82(5):346-53
pubmed: 15298225
Lancet. 2017 Dec 2;390(10111):2472-2480
pubmed: 28965718
BMC Public Health. 2017 Jan 5;17(1):23
pubmed: 28056940
Lancet Glob Health. 2017 Oct;5(10):e969
pubmed: 28911760
Annu Rev Microbiol. 2014;68:317-36
pubmed: 25208300
PLoS Negl Trop Dis. 2016 Sep 22;10(9):e0004781
pubmed: 27657909
Lancet Glob Health. 2014 Oct;2(10):e570-80
pubmed: 25304633
Trends Microbiol. 2014 Nov;22(11):648-55
pubmed: 25065707
Am J Trop Med Hyg. 2014 Oct;91(4):729-37
pubmed: 25002303
Cochrane Database Syst Rev. 2018 May 31;5:CD001261
pubmed: 29851031
Clin Infect Dis. 2015 Aug 1;61(3):393-402
pubmed: 25870324
Lancet Infect Dis. 2017 Oct;17(10):1042-1052
pubmed: 28818544
Expert Rev Vaccines. 2018 Aug;17(8):673-676
pubmed: 29972655
Wkly Epidemiol Rec. 2008 Feb 8;83(6):49-59
pubmed: 18260212
Clin Infect Dis. 2010 Jan 15;50(2):241-6
pubmed: 20014951
BMJ Open. 2017 Jul 2;7(6):e016283
pubmed: 28674145
PLoS One. 2014 Dec 08;9(12):e114702
pubmed: 25486292
Lancet Glob Health. 2017 Mar;5(3):e310-e323
pubmed: 28193398
BMC Infect Dis. 2016 Dec 5;16(1):732
pubmed: 27919235
N Engl J Med. 2001 Apr 26;344(17):1263-9
pubmed: 11320385
Clin Infect Dis. 2015 Nov 1;61 Suppl 4:S251-8
pubmed: 26449939
J Glob Health. 2012 Jun;2(1):010401
pubmed: 23198130
Travel Med Infect Dis. 2009 Jan;7(1):40-3
pubmed: 19174300
PLoS Negl Trop Dis. 2015 Apr 24;9(4):e0003748
pubmed: 25909750
J Clin Microbiol. 2015 Jan;53(1):262-72
pubmed: 25392358
Clin Infect Dis. 2015 Nov 1;61 Suppl 4:S363-71
pubmed: 26449953